Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display.
暂无分享,去创建一个
K Dane Wittrup | Payal Garg | David W. Colby | V. Ingram | K. Wittrup | A. Messer | Payal Garg | Vernon M Ingram | Ginger Chao | David W Colby | Anne Messer | Tina Holden | Jack M Webster | J. M. Webster | Ginger Chao | T. Holden
[1] T. Rabbitts,et al. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation , 2003, The EMBO journal.
[2] H. Lehrach,et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[3] Andrew J. Martin,et al. Antibody-antigen interactions: contact analysis and binding site topography. , 1996, Journal of molecular biology.
[4] R L Stanfield,et al. Antibody-antigen interactions: new structures and new conformational changes. , 1994, Current opinion in structural biology.
[5] T. Rabbitts,et al. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. , 2002, Journal of molecular biology.
[6] D. Curiel,et al. Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target , 2000, Cancer Gene Therapy.
[7] Eric T. Boder,et al. Yeast surface display for screening combinatorial polypeptide libraries , 1997, Nature Biotechnology.
[8] Hans Lehrach,et al. Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.
[9] K D Wittrup,et al. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[10] K D Wittrup,et al. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. , 1999, Journal of molecular biology.
[11] S. Jobling,et al. Immunomodulation of enzyme function in plants by single-domain antibody fragments , 2003, Nature Biotechnology.
[12] K. Wittrup,et al. Rapid Method for Measuring ScFv Thermal Stability by Yeast Surface Display , 2003, Biotechnology progress.
[13] T. Rabbitts,et al. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. , 2003, Journal of molecular biology.
[14] S E Hufton,et al. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. , 2001, Journal of molecular biology.
[15] M. Willingham,et al. I ntrabody‐based strategies for inhibition of vascular endothelial growth factor receptor‐2: effects on apoptosis, cell growth, and angiogenesis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[16] D. Housman,et al. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[18] C. Raymond,et al. General method for plasmid construction using homologous recombination. , 1999, BioTechniques.
[19] M. Schiffer,et al. Structure and properties of human immunoglobulin light-chain dimers. , 1995, Methods in molecular biology.
[20] D. Danley,et al. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. , 1999, Journal of immunological methods.
[21] Michele C. Kieke,et al. Directed evolution of a stable scaffold for T-cell receptor engineering , 2000, Nature Biotechnology.
[22] Sachdev S Sidhu,et al. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. , 2002, Journal of molecular biology.
[23] P. Patterson,et al. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] Lucy J. Holt,et al. Domain antibodies: proteins for therapy. , 2003, Trends in biotechnology.
[25] H R Hoogenboom,et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. , 1991, Journal of molecular biology.
[26] Kurt S. Thorn,et al. ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions , 2001, Bioinform..
[27] Martin R. Johnson,et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[29] K. Wittrup,et al. Fine Affinity Discrimination by Yeast Surface Display and Flow Cytometry , 2000, Biotechnology progress.
[30] K Dane Wittrup,et al. Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* , 2004, Journal of Biological Chemistry.
[31] Andreas Plückthun,et al. Biophysical properties of human antibody variable domains. , 2003, Journal of molecular biology.
[32] Ronald Wetzel,et al. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Cochran,et al. Domain-level Antibody Epitope Mapping through Yeast Surface Display of Epidermal Growth Factor Receptor Fragments , 2022 .
[34] K. Wittrup,et al. Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. , 2004, Nucleic acids research.
[35] D. Housman,et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] Bin Yuan,et al. Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody Fragments† , 2004 .
[37] H. Steven Wiley,et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library , 2003, Nature Biotechnology.
[38] A. Plückthun,et al. Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. , 1999, Journal of molecular biology.
[39] R. Kopito,et al. Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.
[40] R L Stanfield,et al. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[41] J. Roth,et al. Gene replacement therapy for non-small cell lung cancer: a review. , 2004, Hematology/oncology clinics of North America.
[42] R. Murphy,et al. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. , 2004, Brain research. Molecular brain research.
[43] I. Wilson,et al. Antibody-antigen interactions , 1993 .
[44] A. Rajpal,et al. Intracellular Stability of Anti-caspase-3 Intrabodies Determines Efficacy in Retargeting the Antigen* , 2001, The Journal of Biological Chemistry.
[45] David W. Colby,et al. Engineering antibody affinity by yeast surface display. , 2004, Methods in enzymology.
[46] K D Wittrup,et al. Yeast surface display for directed evolution of protein expression, affinity, and stability. , 2000, Methods in enzymology.
[47] A. Plückthun,et al. Domain interactions in antibody Fv and scFv fragments: effects on unfolding kinetics and equilibria , 1999, FEBS letters.
[48] W. Marasco,et al. Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. , 2004, Journal of molecular biology.
[49] T. Terwilliger,et al. Engineering soluble proteins for structural genomics , 2002, Nature Biotechnology.